Table 3.
Summary of data obtained from different studies on kidney dosimetry for 177Lu octreotate
| The present study, Gothenburg | Valkema et al., Rotterdam[[18]] | Garkavij, et al., Lund[[20]] | Sandström et al., Uppsala[[19]] | Wehrmann et al., Bad Berka[[17]] | Cremonesi et al., Milan[[15]] | |
|---|---|---|---|---|---|---|
| Kidney protection |
Lysine, arginine |
Lysine, arginine |
Vamin |
Vamin |
Lysine, arginine |
ND |
| Number of patients |
33 |
37 |
16 |
24 |
61 |
10 |
|
Aadministered/treatment cycle (GBq) mean (range) |
(3.4 to 8.2) |
(1.8 to 7.4) |
7.4 |
7.4 |
5.4 (2.5 to 7.4) |
(3.7 to 7.4) |
| Treatment cycles per patient |
1 to 5 |
3 to 7 |
2 to 4 |
Only first treatment cycle |
1 to 4 |
ND |
|
D/Aadministered (Gy/GBq) mean (SD) |
0.80 (0.30), 0.60 (0.17)* |
|
0.97 (0.24), 1.15 (0.29)*, 0.81 (0.21)**, 0.90 (0.21)*** |
0.98 (0.73), 0.71 (0.25)*, 0.65 (0.25)** |
0.9 (0.3) |
0.62 (median) |
|
D/Aadministered (Gy/GBq) range |
0.33 to 2.4 Gy/GBq, 0.29 to 1.2 Gy/GBq* |
7.3 to 27 Gy |
|
2.4 to 13 Gy (right)** |
0.5 to 1.7 Gy/GBq |
0.45 to 18 Gy/GBq (median range) |
|
D/Aadministered for treatment cycle 1 (Gy/GBq) mean (range) (SD) |
0.84 (0.38 to 1.7) (0.29) |
|
|
0.98 (0.73), 0.71 (0.25)*, 0.65 (0.25)** |
|
|
| Imaging time points |
1 h, days 1, 2, and 7 |
ND, but several days |
0.5 h, days 1, 4, and 7 (treatment cycle 1 to 2) days 1,and 4 (treatment cycle 3 to 4) SPECT at day1 and/or day 4 |
1 h, days 1, 4, and 7 (treatment cycle 1) SPECT at all time points |
0, 3, 20, 44, and 68 h |
up to 48 h |
| Scintigraphic method |
Planar imaging |
Planar imaging |
Planar imaging, SPECT |
Planar imaging, SPECT |
Planar imaging |
Planar imaging |
| Quantification method |
CV, *PA, CT for kidney mass |
CV |
CV attenuation map CT for kidney mass, *different background, **SPECT to scale the time-activity curve, ***SPECT for voxel dosimetry |
*SPECT organ VOI, **SPECT small VOI (4 cm3) |
CV |
CV |
| Dosimetry | MIRD | MIRDOSE3 | MIRD | OLINDA | MIRD 16, MEDISO, OLINDA with S values for absorbed dose calculation | OLINDA/EXM |
CV, conjugate-view method; PA, posterior-anterior view method; Aadministered, administered activity; D, mean absorbed dose; ND, not defined. Note that some studies give data in Gy and other in Gy/GBq, and some use mean values while other use median values. The asterisk (*) is for guiding the reader, which quantification method was used in providing the mean absorbed doses in each study compared.